Biotech Values

[Biowatch]

I assume DNDN will get there first (if the 9902b data is good) because NWBT has approval to start a Ph III in prostate cancer. The implication is that they haven't started the trial, so DNDN is much farther along.

The approval of DCVax®-Brain implies that immunotherapy hasn't been written off as an approach.

>>NWBT is already at the Phase III, pivotal trial stage in prostate cancer...

Clinical trial data to date in hormone independent prostate cancer patients have shown striking results similar to the results in brain cancer...

2. DCVax®-Prostate, a personalized dendritic cell vaccine for treatment
of hormone independent non-metastatic prostate cancer, which has been
cleared by the FDA to enter a Phase III pivotal clinical trial in the
US.<<